The efficacy of teneligliptin in patients with type 2 diabetes mellitus

The efficacy of teneligliptin in patients with type 2 diabetes mellitus - The efficacy of teneligliptin in patients with type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000028763

Enrollment

Registered

2017-08-28

Start date

2017-08-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with type 2 diabetes with HbA1c=> 7% at the time of consenting 2.Female and male patients over 20 years old 3.Patients have been taking daily linagliptin for more than 12 weeks 4.Patients who can provide their written consent for participation of this study

Exclusion criteria

Exclusion criteria: 1.Patients with history of hypersensitivity to teneligliptin 2.Patients with diabetic ketoacidosis, diabetic coma, or bofore coma, type1 diabetes 3.Severe infection, before and not long after surgery, or patient with severe trauma 4.Women with during pregnancy , nursing, or pregnant likelihood 5.Patients with severe renal dysfunction ,end stage renal disease during dialysis 6.Patients with severe liver dysfunction 7.Inadequte patient judged by doctor

Design outcomes

Primary

Measure	Time frame
Amount of change in HbA1c after administration 24 weeks later	—

Secondary

Measure	Time frame
Casual blood glucose, glycoalbumin Serum lipid level(total cholesterol, LDL-cholesterol, triglyceride, HDL-cholesterol) Urinary albumin, urinary L-FABP The incidence of side effects	—

Countries

Japan

Contacts

Public ContactHajime Koyano

Juntendo University Urayasu Hospital Endocrinology and Diabetology

koyano@juntendo-urayasu.jp047-353-3111

Outcome results